Bevacizumab for recurrent or refractory malignant glioma

Bevacizumab for recurrent or refractory malignant glioma - Bevacizumab for recurrent or refractory malignant glioma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017100

Enrollment

Registered

2015-04-10

Start date

2010-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent or recurrent malignant glioma

Interventions

Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)recurrent malignant glioma 2)>= 20 years old, KPS >=60 3)recurrence after TMZ or ACNU chemotherapy 4)>=4 weeks after craniotomy 5)obtained written IC (1)Neu >=2000/mm3 (2)Plt >=100000/mm3 (3)Hb >=9.0mg/dL (4)T.bil >=1.5mg/dL (5)AST, ALT =<100IU/L (6)PT-INR =<1.5 (7)Serum Cr =<1.5mg/dL (8)Proteinuria =<1+

Exclusion criteria

Exclusion criteria: 1)ICH, =< 6 month after stroke 2)severe wound, ulcer, fracture 3)bleeding 4) >= 6 month after myocardiac infarction or pulmonary embolism 5)heart failure >= NYHA grade 2 6)uncontrollable hypertention 7)uncontrollable gastric ulcer 8)=< 1 year after gastrointestinal perforation 9)pregnant or conducting breastfeeding 10)already treated by Bevacizumab in the past

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
response rate, 6 month progression free survival, 6 month overall survival, safetiness	—

Countries

Japan

Contacts

Public ContactAkitake Mukasa

The University of Tokyo Hospital Department of Neurosurgery

mukasa-nsu@umin.ac.jp+81-5800-8853

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026